All Stories

  1. Loss-of-function mutations in ndh do not confer delamanid, ethionamide, isoniazid, or pretomanid resistance in Mycobacterium tuberculosis
  2. The small non-coding RNA B11 regulates multiple facets of Mycobacterium abscessus virulence
  3. Reply: Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing ofM. tuberculosis
  4. Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis
  5. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement
  6. Updating the WHO target product profile for next-generation Mycobacterium tuberculosis drug susceptibility testing at peripheral centres
  7. Designing molecular diagnostics for current tuberculosis drug regimens
  8. Transcriptional regulation and drug resistance in Mycobacterium tuberculosis
  9. A crowd of BashTheBug volunteers reproducibly and accurately measure the minimum inhibitory concentrations of 13 antitubercular drugs from photographs of 96-well broth microdilution plates
  10. Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment
  11. The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis
  12. Role of Epistasis in Amikacin, Kanamycin, Bedaquiline, and Clofazimine Resistance in Mycobacterium tuberculosis Complex
  13. Making IGRA testing easier: First performance report of QIAreach QFT for tuberculosis infection diagnosis
  14. Is the new WHO definition of extensively drug-resistant tuberculosis easy to apply in practice?
  15. A PGE2-MEF2A axis enables context-dependent control of inflammatory gene expression
  16. A New Model of Chronic Mycobacterium abscessus Lung Infection in Immunocompetent Mice
  17. How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide
  18. Guidance for Studies Evaluating the Accuracy of Rapid Tuberculosis Drug-Susceptibility Tests
  19. Whole genome sequencing in Mycobacterium tuberculosis
  20. Fluoroquinolone heteroresistance in Mycobacterium tuberculosis: detection by genotypic and phenotypic assays in experimentally mixed populations
  21. Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues
  22. Building the framework for standardized clinical laboratory reporting of next generation sequencing data for resistance-associated mutations in Mycobacterium tuberculosis complex
  23. Evolution of programmatic definitions used in tuberculosis prevention and care
  24. Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase
  25. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing
  26. Drug resistance mechanisms and drug susceptibility testing for tuberculosis
  27. Role of Disputed Mutations in the rpoB Gene in Interpretation of Automated Liquid MGIT Culture Results for Rifampin Susceptibility Testing of Mycobacterium tuberculosis
  28. Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study
  29. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis
  30. Evaluation of a novel line probe assay to detect resistance to pyrazinamide, a key drug used for tuberculosis treatment
  31. Evolution of Phenotypic and Molecular Drug Susceptibility Testing
  32. Reaching consensus on drug resistance conferring mutations
  33. Reaching consensus on drug resistance conferring mutations
  34. Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives
  35. Accelerating tuberculosis elimination in low-incidence settings: the role of genomics
  36. Collaborative Effort for a Centralized Worldwide Tuberculosis Relational Sequencing Data Platform: Figure 1.
  37. Lab-on-Chip-Based Platform for Fast Molecular Diagnosis of Multidrug-Resistant Tuberculosis
  38. Diagnostic Performance of the New Version (v2.0) of GenoType MTBDRslAssay for Detection of Resistance to Fluoroquinolones and Second-Line Injectable Drugs: a Multicenter Study
  39. PhyResSE: a Web Tool Delineating Mycobacterium tuberculosis Antibiotic Resistance and Lineage from Whole-Genome Sequencing Data
  40. Drug Resistance in Mycobacterium tuberculosis
  41. Integration of Published Information Into a Resistance-Associated Mutation Database for Mycobacterium tuberculosis
  42. MicroRNA induction in human macrophages associated with infection with ancient and modern TB strains
  43. Utility of propidium monoazide viability assay as a biomarker for a tuberculosis disease
  44. Use of genetic mutations for prediction of resistance to pyrazinamide in M. tuberculosis strains
  45. Mycobacterium tuberculosis Pyrazinamide Resistance Determinants: a Multicenter Study
  46. miRNA Signatures in Sera of Patients with Active Pulmonary Tuberculosis
  47. The roles of microRNAs on tuberculosis infection: Meaning or myth?
  48. Alteration of human macrophages microRNA expression profile upon infection with Mycobacterium tuberculosis
  49. Mycobacterium tuberculosis Beijing Genotype Is Associated with HIV Infection in Mozambique
  50. Genome-Wide Discovery of Small RNAs in Mycobacterium tuberculosis
  51. Early tuberculosis treatment monitoring by Xpert® MTB/RIF: Figure 1–
  52. A Genome-Wide Identification Analysis of Small Regulatory RNAs in Mycobacterium tuberculosis by RNA-Seq and Conservation Analysis
  53. GenoType MTBDRslperformance on clinical samples with diverse genetic background
  54. Is multidrug-resistant tuberculosis on the rise in Mozambique? Results of a national drug resistance survey
  55. Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is "blind" treatment dangerous?
  56. Molecular diversity of Mycobacterium tuberculosis isolates from patients with pulmonary tuberculosis in Mozambique
  57. Molecular detection of rifampin and isoniazid resistance to guide chronic TB patient management in Burkina Faso
  58. Identificazione molecolare di mutazioni conferenti resistenza a rifampicina ed isoniazide in M. tuberculosis in campioni clinici diretti mediante Genotype MTBDR (Hain Lifescience)
  59. Genotype MTBDRplus: a Further Step toward Rapid Identification of Drug-Resistant Mycobacterium tuberculosis
  60. Use of Genotype MTBDR Assay for Molecular Detection of Rifampin and Isoniazid Resistance in Mycobacterium tuberculosis Clinical Strains Isolated in Italy